Multiple Cycles of Dose-Intensive Cyclophosphamide, Etoposide, and Cisplatinum (DICEP) Produce Durable Responses in Refractory Non-Hodgkin's Lymphoma

References

• The Non-Hodgkins Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification ofnon-Hodgkin's lymphomas. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Kalter S., Holmes L, Cabanillas F. Long-term results of treatment of patients with follicular lymphomas. Hematol Oncol 1987; 5: 127
   PubMed Web of Science ®Google Scholar
• De Vita V T, Hubbard S M, Longo D L. The chemotherapy of lymphomas: Looking back, moving forward. Cancer Res 1987; 47: 5810–5824
   PubMed Web of Science ®Google Scholar
• O'Donnell M R, Forman S J, Levine A M, et al. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma. Cancer Treat Rep 1987; 71: 187–189
   PubMedGoogle Scholar
• Cabanillas F, Hagemeister F B, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1982; 5: 693–697
   Google Scholar
• Philip T, Armitage J O, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Phillips G L, Fay J W, Herzig R H, et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75(4)831–838
   PubMed Web of Science ®Google Scholar
• Colombat P, Gorin N-C, Lemonnier M-P, et al. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas. J Clin Oncol 1990; 8(4)630–637
   PubMed Web of Science ®Google Scholar
• Gingrich R D, Ginder G D, Burns L J, et al. BVAC ablative chemotherapy followed by autologous bone marrow transplantation for patients with advanced lymphoma. Blood 1990; 75: 2276–2281
   PubMed Web of Science ®Google Scholar
• Petersen F M, Applebaum F R, Hill R, et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8(4)638–647
   PubMed Web of Science ®Google Scholar
• Gulati S C, Shank B, Black P, et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6(8)1303–1313
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage J O, Smith D M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74(4)1260–1265
   PubMed Web of Science ®Google Scholar
• Armitage J O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73(7)1749–1758
   PubMed Web of Science ®Google Scholar
• Takvorian T, Canellos G P, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316(24)1499–1505
   PubMed Web of Science ®Google Scholar
• Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6(7)1118–1124
   PubMed Web of Science ®Google Scholar
• Freedman A S, Takvorian T, Anderson K C, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8(5)784–791
   PubMed Web of Science ®Google Scholar
• Neidhart J A, Kohler W, Stidley C, et al. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990; 8(10)1728–1738
   PubMed Web of Science ®Google Scholar
• Neidhart J A, Mangalik A, Kohler W, et al. Granulocyte colony-stimulating factor (rhG-CSF) stimulates recovery of granulo-cytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989; 7(11)1685–1692
   PubMed Web of Science ®Google Scholar
• Neidhart J A, Mangalik A, Stidley C A, et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor (GM-CSF) to support dose-intensive chemotherapy. J Clin Oncol 1992; 10(9)1460–1469
   PubMed Web of Science ®Google Scholar
• Neidhart J A. Dose intensive treatment of breast cancer supported by granulocyte macrophage colony-stimulating factor. Breast Cancer Treatment, in press
   Google Scholar
• Gagen M, Gouchnour D, Young D, et al. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy induced vomiting. J Clin Oncol 1984; 2(6)696–701
   PubMed Web of Science ®Google Scholar
• Cox D R, Oakes D. Analysis of survival data. Chapman and Hall, London 1984
   Google Scholar
• SAS Institute Inc. SAS User's Guide. Statistics, Version 5 Edition. SAS Institute, Cary, NC 1985
   Google Scholar
• Ho A D, Del Valle F, Engelhard M, et al. Mitoxantrone/high dose ARA-C and recombinant human GM-CSF in the treatment of re-fractory non-Hodgkin's lymphoma. Cancer 1990; 66: 423–430
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Hagemeister F B, Bodey G P, et al. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
   PubMed Web of Science ®Google Scholar
• Collins C, Mortimer J, Livingston R B. High-dose cyclophospha-mide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer 1989; 63: 228–232
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin J H, Churchill W H, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 1990; 8(4)648–656
   PubMed Web of Science ®Google Scholar
• Teicher B A, Holden S A, Eder J P, et al. Influence of schedule on alkylating agent cytotoxicity in-vitro and in-vivo. Cancer Res 1989; 49: 5994–5998
   PubMed Web of Science ®Google Scholar
• Voelcker F, Wagnor T, Weintzek C, et al. Correlation of human pharmacokinetics of activated cyclophosphamide and therapeutic efficacies. Cancer 1984; 54: 1179–1186
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Berard C W, Brown B W, Jr., et al. National Cancer Institute sponsored study of classification of non-Hodgkins lymphoma. Cancer 1982; 29: 2112
   Google Scholar